The reason for investing in Ocugen (NASDAQ:OCGN) stock hasn’t changed. Bulls expect the FDA to allow Ocugen to market Bharat Biotech’s Covaxin vaccine in the U.S., enabling Ocugen to generate massive sales and rapidly boost OCGN stock.   Source: shutterstock.com/PhotobyTawat The problems with this thesis, though, remain the same as they’ve ever been. Despite a great
0 Comments
SmileDirectClub (NASDAQ:SDC) is an oral care company founded in 2014. Headquartered in Nashville, the company operates in the North America, Europe and Asia Pacific regions. Its primary offering is a clear aligner therapy treatment, but it also sells a variety of oral care products, such as whitening kits and gels, toothbrushes, toothpastes and water flossers. SDC
0 Comments
Big Oil has been out of favor for over a decade. But on the reopen, are the analysts finally bullish? Visit our website: https://www.zacks.com Visit our Stocktwits account: https://stocktwits.com/ZacksResearch Check out our weekly promotion: https://www.zacks.com/promo If you’re interested in our services, please check out Zacks Ultimate: https://www.zacks.com/ultimate/?adid=YOUTUBE&cid=sm-YOUTUBE
0 Comments
Investors seeking exposure to the Hong Kong stock market might consider exchange-traded funds (ETFs). Historically, Hong Kong has thrived as a global financial center and capitalist economy, and it largely has continued to do so since it became a semi-autonomous region of China in 1997. But during the past two years, Hong Kong’s democratic government
0 Comments
Former hedge fund manager Nelson Saeirs’ paintings visually represent the volatility trading algorithms he used on Wall Street. This one is titled, “The VIX over 40.” A reading in the VIX volatility index over 40 has historically preceded huge market losses Source: Nelson Saiers If there ever was a year active management should have outperformed
0 Comments
Barry Silbert, Founder and CEO, Digital Currency Group  David A. Grogan | CNBC Digital Currency Group is selling shares to SoftBank and Google’s venture capital arm in a deal that values the crypto conglomerate at more than $10 billion.  The Manhattan-based, private company announced a secondary round on Monday, in which existing investors are selling
0 Comments
Given the potential, tremendous benefits of Cassava’s Alzheimer’s drug for millions of patients and the high probability of the drug being approved, I believe that Cassava Sciences (NASDAQ:SAVA) stock is vastly undervalued. Source: Pavel Kapysh / Shutterstock.com Additionally, my calculations indicate that the shares could easily soar over 200x after the company’s Alzheimer’s treatment, simufilam,
0 Comments
Early in October, I said that Cassava Sciences’ (NASDAQ:SAVA) big gains in late September had investors dreaming of a big payday for SAVA stock in 2022.  Source: Pavel Kapysh / Shutterstock.com I even suggested it might retest $100—a level it hit throughout the summer—by the end of 2021. I was convinced it would go on
0 Comments